This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

This study has been terminated.
Information provided by:
Servier Identifier:
First received: September 12, 2005
Last updated: April 5, 2017
Last verified: April 2017
The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

Condition Intervention Phase
Mild Cognitive Impairment Drug: S18986 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period

Further study details as provided by Servier:

Primary Outcome Measures:
  • Episodic memory

Secondary Outcome Measures:
  • Other cognitive domains, activities of daily living, global impression of change, MRI, safety.

Enrollment: 38
Study Start Date: June 2005
Study Completion Date: March 29, 2006
Primary Completion Date: March 29, 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Memory complaint
  • Acetylcholinesterase inhibitors stopped at least 3 months before selection

Exclusion Criteria:

  • Dementia
  • Parkinson's disease
  • Vascular disorder
  • Depression
  • Epilepsy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00202540

Hôpital la Grave-Casselardit
Toulouse, France, 31000
Sponsors and Collaborators
Institut de Recherches Internationales Servier
Study Chair: Bruno Vellas, MD Hôpital la Grave-Casselardit, Toulouse
  More Information Identifier: NCT00202540     History of Changes
Other Study ID Numbers: CL2-18986-009
Study First Received: September 12, 2005
Last Updated: April 5, 2017

Additional relevant MeSH terms:
Cognition Disorders
Mild Cognitive Impairment
Neurocognitive Disorders
Mental Disorders processed this record on August 23, 2017